17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 17,442 shares of the company’s stock, valued at approximately $71,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ZURA. AQR Capital Management LLC purchased a new stake in shares of Zura Bio during the 2nd quarter worth $43,000. SG Americas Securities LLC purchased a new position in Zura Bio in the third quarter valued at about $62,000. Renaissance Technologies LLC raised its holdings in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares in the last quarter. Valence8 US LP purchased a new stake in shares of Zura Bio during the third quarter valued at about $71,000. Finally, Palumbo Wealth Management LLC bought a new stake in shares of Zura Bio in the 3rd quarter valued at about $156,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZURA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a research report on Monday, November 18th. Leerink Partners began coverage on Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Chardan Capital decreased their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Zura Bio Trading Up 0.8 %

NASDAQ:ZURA opened at $2.51 on Wednesday. Zura Bio Limited has a 12 month low of $2.00 and a 12 month high of $6.35. The firm has a fifty day simple moving average of $3.69 and a 200-day simple moving average of $3.74.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). On average, sell-side analysts predict that Zura Bio Limited will post -0.65 earnings per share for the current year.

Insider Transactions at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 22.10% of the company’s stock.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.